Anand Patel
@anand-88-patel
Leukemia & myeloid malignancy doctor. posts=mine. Repost≠endorsement. He/him.
Day 9 - APOLLO trial in high-risk APL ascopubs.org/doi/abs/10.1...
Day 8 - Aza + TAG +/- VEN for AML pubmed.ncbi.nlm.nih.gov/38052038/
Day 7 - HMA + VEN in R/R T-cell ALL pubmed.ncbi.nlm.nih.gov/41338863/
Day 6 - outcomes in accelerated/blast-phase MPNs in the current era of therapy pubmed.ncbi.nlm.nih.gov/38739724/
Day 5: the PRISM score in AML treated with HMA + VEN pubmed.ncbi.nlm.nih.gov/42391582/
Day 4: decitabine + ven + ponatinib in advanced CML/Ph+ AML pubmed.ncbi.nlm.nih.gov/39303729/
Day 3: real-world outcomes of R/R CBF AML pubmed.ncbi.nlm.nih.gov/40062542/
A two-week stretch of inpatient leukemia service begins! Day 1 - outcomes in MECOMr AML pubmed.ncbi.nlm.nih.gov/40983567/
useful article in @bloodjournals.hematology.org from the ROCCA consortium evaluating the benefit of TKI maintenance post CART for Ph+ ALL pubmed.ncbi.nlm.nih.gov/42349018/
Day 2 of LL&M Great Debates! I will be speaking in a debate focused on the use of venetoclax in high-risk MDS www.hmpglobalevents.com/llmgreatdeba...
Looking forward to being part of the leukemia case discussion panel at LL&M Great Debates in NYC later today! www.hmpglobalevents.com/llmgreatdeba...
please join us on June 30th for a Ph+ ALL focused session! ashconnections.hematology.org/networks/eve...
Check out this @americancancersoc.bsky.social podcast focused on post-MPN AML that I was a part of! cancerspeak.podbean.com/e/post-mpn-a...
glad to be speaking at an upcoming NCCN Patient Webinar on MPNs! Registration link here - www.nccn.org/patientresou...
Check out this multi-center analysis focused on CV outcomes in patients with AML treated with HMA + VEN! www.sciencedirect.com/science/arti...
check out the NCCN AML insights article focused on MRD! pubmed.ncbi.nlm.nih.gov/42297017/
happy to contribute to this effort looking at outcomes in patients with hairy cell leukemia! pubmed.ncbi.nlm.nih.gov/42281276/
More data for HMA + VEN + menin inhibitor in R/R AML (this time ASTX727 + VEN + revumenib for KMT2Ar, NPM1, or NUP98r) ascopubs.org/doi/10.1200/...
a promising early-phase study of HMA + VEN + NAV in advanced myeloid malignancies including accelerated/blast-phase MPNs aacrjournals.org/clincancerre...
Early-phase experience of Aza + Ven + Zifto in R/R NPM1m AML is out! ashpublications.org/blood/articl...
the Phase III SENTRY study of Rux +/- selinexor in JAK inhibitor naive MF is out! -higher SVR35 with combo but no difference in symptom improvement -separation of survival curves but follow-up is still short ascopubs.org/doi/10.1200/...
Proud of one of our amazing IM residents Dr Apoorva Ravichandran for presenting our experience using cytarabine-mitoxantrone-venetoclax for patients with R/R AML! www.asco.org/abstracts-pr...
a promising prospective study of Ven + pediatric inspired regimen in pts with newly diagnosed ALL aged 14-60! ashpublications.org/blood/articl...
very helpful consensus article in @bloodjournal.bsky.social regarding CART in adult patients with ALL! ashpublications.org/blood/articl...
a report of 95 adult patients with NUP98r AML! www.nature.com/articles/s41...
really enjoyed being a part of this session focused on AML organized by the Patient Empowerment Network! powerfulpatients.org/resource/ins...
Excited to the part of the 2026 @mpnrf.bsky.social roundtable and participating as part of the unmet needs panel!
long-term follow-up of CALGB 10403 in AYA patients with ALL now out in @bloodjournals.hematology.org! pubmed.ncbi.nlm.nih.gov/42101912/